ertugliflozin (Steglatro) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Ertugliflozin (PF-04971729) is a potent and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. SGLT2 has become an important therapeutic target and several SGLT2-selective inhibitors are either approved or in clinical development for the management of blood glucose in patients with type 2 diabetes. Ertugliflozin demonstrated robust urinary glucose excretion in rats and an excellent preclinical safety profile. It was announced that FDA and EMA filing acceptances of three marketing applications for ertugliflozin-containing medicines for adults with type 2 diabetes.   NCATS

Chemistry

  • SMILES: CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)C=C1
  • InChIKey: MCIACXAZCBVDEE-CUUWFGFTSA-N
  • Mol. Mass: 436.883
  • ALogP: 1.36
  • ChEMBL Molecule:
    ertugliflozin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1.3064
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol | ertugliflozin | ertugliflozin l-pyroglutamic acid | ertugliflozin l-pyroglutamic acid/ metformin hydrochloride | ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate | pf04971729 | pf 04971729 | pf-04971729 | pf-04971729-00

Organizations (29)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (27)


 

Adult (Phase 1)

Atherosclerosis (Phase 4)

Body Weight Changes (Phase 4)

Cardiac Resynchronization Therapy (Phase 3)

Cardiovascular Diseases (Phase 4)

Defibrillators, Implantable (Phase 3)

Diabetes Mellitus, Type 2 ()

Diabetic Nephropathies (Phase 4)

Drugs, Investigational (Phase 4)

Glycemic Control (Phase 4)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 3)

Heart Failure, Diastolic (Phase 4)

Heart Failure, Systolic (Phase 4)

Hypertension (Phase 4)

Hypertrophy, Left Ventricular (Phase 3)

Insulin Resistance (Phase 4)

Kidney (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 1)

Liver (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 1)

Mitral Valve Insufficiency (Phase 3)

Sleep Apnea Syndromes (Phase 4)

Sodium-Glucose Transporter 2 Inhibitors (Phase 4)

Waist Circumference (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 37
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue